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E-mail address: Hezhimin2005@yahoo.com (Z. HeWe previously demonstrated that 14-3-3r was downregulated in 5-ﬂuorouracil (5-Fu)-resistant
MCF-7 breast cancer cells (MCF-7/5-Fu). Here, we found that stably enhanced 14-3-3r expression
strengthened the effects of 5-Fu, Mitoxantrone and cDDP. 14-3-3r stabilised the p53 protein and
bound Akt to inhibit its activity and its downstream targets: survivin, Bcl-2 and NF-jB-p50. In addi-
tion, decreased p53 expression, but not promoter hypermethylation, was responsible for the down-
regulation of 14-3-3r in MCF-7/5-Fu cells. Meanwhile, initial treatments with high concentrations of
5-Fu clearly induced 14-3-3r and p53 expression in a time-dependent manner. 14-3-3r-mediated
molecular events that synergise with p53 may play important roles in the chemotherapy of breast
cancer.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Breast cancer is the second leading cause of cancer deaths in
women, and its incidence rate is increasing in most countries [1].
Chemotherapy is a very important therapeutic option for almost
all breast cancer patients. However, the development of multidrug
resistance usually results in the failure of chemotherapy, even after
combination chemotherapy, which leads to tumour recurrence and
further progression. Although the mechanisms responsible for
multidrug resistance have been investigated intensely over the
past 50 years, the clinical causes of multidrug resistance are still
not completely understood [2,3].
In our previous study, we sought to clarify the mechanisms
responsible for drug resistance and identify new biomarkers pre-
dicting the response to 5-Fu. We established a 5-Fu-resistant cell
line (MCF-7/5-Fu) derived from MCF-7 breast cancer cells by step-
wise selection using 5-Fu. The MCF-7/5-Fu cells were also resistant
to Mitoxantrone, cDDP, ADM and TAXOL; we found that this resis-
tance was partly due to BCRP overexpression. Furthermore, using a
comparative proteomic approach, we found that 14-3-3r waschemical Societies. Published by E
titute and Cancer Hospital,
ong, PR China. Fax: +86 020
).signiﬁcantly downregulated in MCF-7/5-Fu cells and that transient
enhancement of 14-3-3r expression could increase the sensitivity
to 5-Fu and cDDP [4].
14-3-3r is a member of the 14-3-3 family of proteins that
includes seven isotypes (a/b, c, e, r, f, s/h, and g). It is highly
conserved in mammals and is involved in a wide range of mamma-
lian pathways, including cell cycle regulation [5]. 14-3-3r (also
called stratiﬁn) was characterised as a human mammary epithe-
lium-speciﬁc marker 1 (HME1), has been found to be directly
related to human cancers and is thought to be a tumour suppressor
because of its decreased expression in several types of human tu-
mours [6]. In response to DNA damage, 14-3-3r is induced in a
p53-dependent manner and prevents the cdc2-cyclin B1 complex
from entering the nucleus and blocking the G2 phase [7,8]. In addi-
tion, 14-3-3r positively regulates p53 and suppresses tumour
growth, indicating that there is a positive feedback between 14-
3-3r and p53 [9], and binds Akt to inhibit Akt mediated cell
growth, transformation and tumourigenesis [10]. Overexpression
of 14-3-3r inhibited NPC (nasopharyngeal carcinoma) cell growth
and sensitised NPC cells to apoptosis induced by the chemothera-
peutic agent 2-methoxyestradiol [11]. William et al. found that
overexpression of 14-3-3r led to relocalisation of EGR2 and down-
regulation of ErbB2 at both the transcript and protein levels [12].
The authors also found that ectopic expression of 14-3-3r results
in restoration of epithelial polarity in ErbB2-transformedlsevier B.V. All rights reserved.
Fig. 1. A signiﬁcant change in 14-3-3r expression was observed in every cell line in response to selected drugs. (A) The 14-3-3r in selected clones indicated that related cell
lines were successfully established. (B–F) Dose-growth rate curves were plotted from the MTS assay results collected from six independent experiments. (C) IC50 values from
six independent experiments. 14-3-3r downregulation with shRNA in MCF-7 cells signiﬁcantly increased the IC50 values for 5-Fu, Mitoxantrone and cDDP. ⁄P < 0.01, N:
P < 0.05.
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within primary epithelial cells increases their proliferative capacity
and adversely affects their ability to form polarised structures [13].Cells lacking the 14-3-3r function have impaired cell cycle control
after DNA damage and increased genomic instability. Other studies
have demonstrated that the loss or downregulation of 14-3-3r
Fig. 2. The proteins involved in 14-3-3r expression change. (A) PI3 K-Akt pathway-related proteins compared between MCF-7 and MCF-7/5-Fu cells. (B) The expression
change of related proteins after change in 14-3-3r expression. (C) Coimmunoprecipitation results demonstrate that 14-3-3r physically binds to Akt. Akt was also shown and
IgG and input were set as controls.
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deletion or mutation [14,15]. In the progression of many human
cancers, 14-3-3r acts as a tumour suppressor. Furthermore, 14-
3-3r may enhance celecoxib-induced apoptosis of glioma cells
via p53 and caspase-3 [16], but the role of 14-3-3r and its exact
mechanism in response to anticancer drugs is still far from being
fully understood. In this study, we investigate the mechanisms
responsible for the 14-3-3r downregulation and the enhancement
of chemotherapeutic sensitivity in MCF-7 breast cancer cells.
2. Materials and methods
2.1. Cell culture and transfection
The human breast cancer cell line MCF-7 was cultured in RPMI
1640 containing 10% foetal bovine serum (Gibco). The drug-resis-
tant derivative line MCF-7/5-Fu was cultured in RPMI 1640 con-
taining 10% foetal bovine serum and 2 mg/l 5-Fu to maintain the
drug resistance. The cells were cultured in 5-Fu-free medium for
at least two weeks before each experiment. MCF-7 cells were
transfected with pGenesil1.1-sh14-3-3r plasmid expressing short
hairpin RNA (shRNA) that speciﬁcally targets 14-3-3r to generate
stable clones with reduced 14-3-3r expression. MCF-7/5-Fu
cells were transfected with PcDNA3.1-14-3-3r plasmid with a
14-3-3r coding sequence to generate stable clones with 14-3-3r
overexpression. In addition, the related control plasmids were
transfected. The transfection was performed with Lipofectamine
2000 (Invitrogen) in accordance with the manufacturer’s instruc-
tions at a ratio of 2 ll of Lipofectamine to 0.8 lg of DNA per well
on a 24-well plate. Twenty-four hours later, the cells were selected
with 800 lg/ml G418 for 2 weeks, and the individual stable clones
were analysed by western blot after the culture was expanded for
further study. In addition, the transient transfection of MCF-7/5-Fucells with the pEGFP-N1-WTp53 plasmid was also performed using
Lipofectamine 2000.
2.2. MTS assay
The CellTiter 96 AQueous One Solution Cell Proliferation Assay
kit (Promega) was used to determine the sensitivity of cells to anti-
cancer drugs. In brief, cells at the exponential growth phase were
seeded in 96-well plates at a density of 5  103 cells/well
(0.18 ml/well) for 24 h before use. The culture medium was
replaced with fresh medium containing anticancer drugs for 48 h.
Then, MTS (20 ll/well) was added. After 2 h further incubation,
the absorbance at 490 nm of each well was recorded on the Bio-
tex ELX800. Growth rate was calculated as the ratio of the absor-
bance of the experimental well to that of the control well. The
IC50 (the concentration of drug that results in 50% of control value)
was also calculated. 5-Fu, Mitoxantrone, cDDP, ADM and TAXOL
were purchased from Sigma.
2.3. RT–PCR
Total RNA was extracted with a Trizol protocol, and cDNA from
the mRNA was synthesized by use of the SuperScript ﬁrst-strand
synthesis system (Fermentas Life Science) for reverse transcrip-
tion–PCR. The primers speciﬁc for 14-3-3r were as follows: 50-
TTGTGGCTGAGAACTGGACA-30 (sense) and 50-ACACCCAGCAGACA
TGCTTT-30 (antisense); for WTp53: 50-GAATATTTCACCCTTCAGATC
CGTGGGC-30 (sense) and 50-TGACCCTTTTTGGACTTCAGGTGGCT-30
(antisense); and for GAPDH: 50-ATTCCATGGCACCGTCAAGGCTGA-
30 (sense) and 50-TTCTCCATGGTGGTGAAGACGCCA-30 (antisense).
The primers and the PCR regents were supplied by TaKaRa Corpo-
ration. The PCR conditions were as follows: 1 cycle at 95 C for
5 min; 28 cycles at 95 C for 45 s, 61 C for 30 s and 72 C
Fig. 3. The regulation of 14-3-3r expression in MCF-7/5-Fu cells. (A) Top, RT-PCR showed 14-3-3r was downregulated at the transcriptional level in MCF-7/5-Fu cells and
MDA-MB-435 cells, which served as a negative control. Middle, location of the primers for MSP analysis of the 14-3-3r gene. Bottom, MSP analysis results, MDA-MB-435
served as a control for fully methylated DNA. (B) Top, RT–PCR showed no signiﬁcant change of p53 in mRNA levels. Bottom, change in molecular events after p53 ectopic
expression.
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solved by electrophoresis in a 2% agarose gel and stained with ethi-
dium bromide.2.4. Western blot
Total proteins were extracted from corresponding cells and
then loaded and separated on 10% SDS–PAGE. The proteins then
were transferred to a PVDF membrane, and the blots were blocked
with 5% non-fat dry milk for 2 h at room temperature. The mem-
branes were then immunoblotted with primary antibodies to
HER2 (Neomarker), PI3K p85 (Santa Cruz Biotechnology), p-PI3K
p85 (Tyr458) (Cell Signaling Technology), Akt (Santa Cruz), p-Akt
(Ser473) (Cell Signaling Technology), surviving (Santa Cruz), Bcl2
(Santa Cruz), NF-kB p50 (Cell Signaling Technology), p53 (Cell
Signaling Technology), 14-3-3r (Santa Cruz) and tubulin (Santa
Cruz) followed by reaction with horseradish peroxidase-conju-
gated secondary antibody (Santa Cruz). The signal was detected
using an ECL detection system (Amersham Biosciences).2.5. Methylation speciﬁc PCR (MSP)
DNA was extracted from cultured MCF-7, MCF-7/5-Fu and
MDA-MB-435 (as a positive control) cells using a DNA kit
(Tiangen). Bisulﬁte treatment and PCR ampliﬁcation were per-
formed as previously described with some modiﬁcations [14]. In
brief, 2 lg genomic DNA was denatured in sodium hydroxide
(NaOH) (0.2 N) for 15 min at 37 C before adding 30 ll hydrochi-
none (20 lM, Sigma) and 520 ll sodium bisulﬁte (3 M, pH 5.0)
which converts unmethylated but not methylated cytosines to ura-
cil. The samples were mixed and incubated at 50 C for 16 h. Mod-
iﬁed DNA was puriﬁed with the Wizard DNA puriﬁcation resin
(Promega), treated with 6.3 ll NaOH (5 N) at room temperature
for 5 min to complete the conversion, precipitated with ethanol
and resuspended in water. Methylation-speciﬁc PCR was per-
formed with primers speciﬁc for either methylated or the modiﬁed
unmethylated DNA spanning the region between CpG dinucleo-
tides 3 and 9 within the 14-3-3r gene (Fig. 3A). The primers spe-
ciﬁc for methylated DNA were the following: 50-TGGTAGTTTT
TATGAAAGGCGTC-30 (sense) and 50-CCTCTAACCGCCCACCACG-30
(antisense); the primers speciﬁc for unmethylated DNA were
the following: 50-ATGGTAGTTTTTATGAAAGGTGTT-30 (sense) and50-CCCTCTAACCACCCACCACA-30 (antisense), which yielded
105-bp and 107-bp PCR products, respectively. The PCR conditions
were as follows: 1 cycle of 95 C for 5 min; 31 cycles of 95 C for
45 s, 56 C for 30 s and 72 C for 30 s; and 1 cycle of 72 C for
4 min. The PCR samples were resolved by electrophoresis in a 2%
agarose gel and stained with ethidium bromide.
2.6. Co-immunoprecipitation
For the co-immunoprecipitation assay, the cells were lysed with
modiﬁed TNE buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 1% Non-
idet P-40 [NP-40], 10 mM sodium ﬂuoride, 10 mM sodium pyro-
phosphate, 2 mM EDTA) supplemented with 1 mg/l leupeptin,
1 mg/l aprotinin, and 1 mM sodium orthovanadate (Na3VO4). The
immunoprecipitations were performed overnight at 4 C with anti-
bodies to Akt or IgG (as a control). The immunoprecipitates were
then incubated for 2 h with protein G-agarose (Amersham Biosci-
ences). The reaction products were washed with lysis buffer, and
the immune complexes were resolved by SDS–PAGE. Subsequently,
western blots were performed.
2.7. Statistical analyses
Quantitative results were expressed as the mean ± standard
deviation. Statistical analyses were carried out with the Statistical
Package for Social Science (SPSS for Windows Version 11.0. USA).
Student’s t-test was used to evaluate the statistical signiﬁcance.
A P value <0.05 or 0.01 was set as the criterion for statistical
signiﬁcance.3. Results
3.1. 14-3-3r enhanced the chemotherapeutic effect of 5-Fu,
Mitoxantrone and cDDP
To explore the exact role of 14-3-3r in the chemotherapeutic
response, stable 14-3-3r overexpression by extraneous transfec-
tion and downregulation with endogenous silencing by RNAi in
various cell lines was established (Fig. 1A). In the MTS assays, the
cells were exposed to different concentrations of anticancer drugs
to examine the growth rate, and the IC50 value for every drug was
calculated. As shown in Fig. 1B-G, 14-3-3r signiﬁcantly increased
Fig. 4. The response to 5-Fu in MCF-7 cells. (A) 5-Fu time-dependently inhibited MCF-7 cell growth, ⁄: vs. 12 h P < 0.05, ⁄⁄: vs. 24 h P < 0.05. (B) Protein expression changes
induced by 5-Fu in MCF-7 cells at different time points.
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causing a signiﬁcant change in the IC50 value. However, in our pre-
vious study, there was no signiﬁcant effect on Mitoxantrone, which
may be due to the small amount of plasmid transfected and short-
term maintenance that did not lead to apparent upregulation of
BCRP expression, which is partly responsible for mediating
Mitoxantrone resistance by an efﬂux mechanism.
3.2. 14-3-3r inhibits Akt activity and that of its downstream target
genes
To explore the signal transduction responsible for drug resis-
tance involving 14-3-3r, differences in the expression of the
HER2/PI3K/Akt pathway-related molecules between MCF-7 and
MCF-7/5-Fu cells were measured (Fig. 2A). We found that there
was no signiﬁcant difference in HER2, total PI3K, phosphor-PI3K
and total Akt between MCF-7 and MCF-7/5-Fu cells. However,
the level of phosphor-Akt (p-Akt) increased in MCF-7/5-Fu cells
and that of p53 decreased. survivin, Bcl-2 and NF-jB-p50 down-
stream of p-Akt and p53 increased. We next asked whether the
PI3K-Akt pathway is affected by 14-3-3r expression. We found
that 14-3-3r overexpression correlated with the increased expres-
sion of p53 and the decreased expression of p-Akt, survivin, Bcl2,
NF-kB-p50 and BCRP in MCF-7/5-Fu cells; the opposite was
observed in MCF-7 cells, which showed decreased expression of
14-3-3r by speciﬁc RNA interference (Fig. 2B). 14-3-3r exerts its
inﬂuence through physical interaction with other proteins. It has
been reported that 14-3-3r could physically bind Akt and inhibit
its activity to stabilise p53 in response to DNA damage [10]. To test
whether this phenomenon also occurs in MCF-7/5-Fu cells, coim-
munoprecipitation experiments were performed, which indicated
that 14-3-3r was detected in the anti-Akt immunoprecipitation
complex, and importantly, the binding level in the Akt immuno-
precipitation complex was tightly associated with 14-3-3r expres-
sion level in different cell lines (Fig. 2C), suggesting that both
endogenous and exogenous 14-3-3r can interact with endogenous
Akt physically to inhibit its activity.
3.3. 14-3-3r downregulation was due to p53 protein expression and
not high methylation levels
In most cancers, the loss of 14-3-3r expression results from
CpG methylation, which plays a crucial role in tumourigenesis.
To determine whether methylation of the 14-3-3r promoter was
responsible for the downregulation of expression of this gene, we
examined the methylation status of the 14-3-3r promoter region.The DNA from another breast cancer cell line, MDA-MB-435,
served as a positive control. No signiﬁcant methylation was
observed in either MCF-7 or MCF-7/5-Fu cells (Fig. 3A). Prior stud-
ies have demonstrated that p53 could positively regulate 14-3-3r
expression in the response to DNA damage [7,11]. In our study, p53
expression in MCF-7/5-Fu cells was downregulated at the protein
level but not at the transcriptional level (Fig. 3B). After transient
transfection of MCF-7/5-Fu cells with a p53 expression vector,
the subsequent p53 protein increase was accompanied by a 14-
3-3r protein increase. Furthermore, p-Akt, NF-kB-p50, Surivivn,
Bcl-2 and BCRP were downregulated by p53 ectopic expression
(Fig. 3B).
3.4. The involvement of 14-3-3r in the anti-cancer activity of 5-Fu
To explore the role of 14-3-3r in MCF-7 cell chemotherapy, the
MTS assay was used to determine the growth rate of MCF-7 cells at
0, 12, 24 and 48 h after a 30-mg/l 5-Fu treatment the results indi-
cated that the anti-proliferate activity of 5-Fu was time-dependent.
Normalised to 0 h, the growth rate at 12, 24 and 48 h was
85.75 ± 8.09%, 63.93 ± 5.88% and 29.81 ± 2.54%, respectively
(Fig. 4A). Western blotting was used to observe changes in the
amount of related proteins after the same treatment at the same
time points (Fig. 4B). 5-Fu treatment can induce the upregulation
of 14-3-3r and p53 synergistically in MCF-7 cells and downregu-
lation of survivin and Bcl-2 in a time-dependent fashion.
Interestingly, the expression of p-Akt and NF-kB-p50 increased
ﬁrst at 12 h and then decreased with time. The increase of p-Akt
and NF-kB-p50may be due to the triggered protection process dur-
ing the initial exposure to 5-Fu.4. Discussion
The high frequency of downregulation of 14-3-3r in several
types of cancer shows that the dysregulation of 14-3-3r plays an
important role in human tumourigenesis, but its role in cancer
treatment and drug resistance is still unclear. Akt also plays a piv-
otal role in cancer formation, and its oncogenic activity results
from the activation of both proliferative and antiapoptotic signal-
ling. Several studies highlight the importance of Akt as a molecular
target for rational cancer therapy. This study showed that Akt
activity (p-Akt (Ser473) was elevated and that 14-3-3r binds
and negatively regulates Akt activity. This important biological
function antagonises Akt-mediated cell survival to enhance the
sensitivity to anticancer drugs.
168 G. Zheng et al. / FEBS Letters 586 (2012) 163–168The 14-3-3 protein family interacts with proteins involved in a
wide variety of signalling pathways of cell cycle and apoptosis.
The known proteins interacting with 14-3-3r, including Cdks [17],
p53 [9], Efp [18] andAkt [10], all play important roles in tumourigen-
esis. Our prior study demonstrated HER2-mediated chemoresis-
tance to 5-Fu, Mitoxantrone and cDDP upregulated BCRP through
the PI3 K/Akt and nuclear factor-kappa B signalling pathways in
MCF7 breast cancer cells [19]. In MCF-7/5-Fu cells, Akt activity (p-
Akt) is much higher, and there is no change in HER2 expression.
We then speculatedas towhether theAkt activity increasewas asso-
ciated with a 14-3-3r decrease. Enhanced expression of 14-3-3r
could downregulate Akt activity, and the coimmunoprecipitation
assays showed that there was a physical interaction, which con-
ﬁrmed the relationship. Akt activity is elevated in several types of
human malignancies, including ovarian, breast, lung, and thyroid
cancers [20]. Akt can mediate phosphorylation of Mdm2, thereby
promoting Mdm2 nuclear localisation and potentiating Mdm2’s
activity in degrading p53 [21]. In addition, NF-kB downstream of
Akt triggers the oncogenesis of Akt [22], partly through positively
regulating the oncogenes involved in cancer radiation resistance
and chemotherapy resistance, such as survivin [23] and bcl-2 [24].
Our study also demonstrated that 14-3-3r regulated resistance
oncogenes through decreasing Akt activity, which is consistentwith
prior studies.
As mentioned above, the dysregulation of 14-3-3r is mostly due
to DNA hypermethylation rather than gene deletion or mutation
[14,15]. Acquiring resistance requires long-term induction in situa-
tions where hypermethylation is responsible for the decrease in 14-
3-3r. TheMSPwas performed but did not show a positive result. To
explore the mechanism responsible for 14-3-3r downregulation,
we focused instead on p53, which was also decreased in MCF-7/5-
Fu cells. We found that ectopic p53 expression regulated 14-3-3r
and related molecules in MCF-7/5-Fu cells, consistent with prior
studies showing positive feedback between 14-3-3r and p53 [11].
The process of acquiring drug resistance is very complex. Once
resistance has been established, the molecules’ status in resistant
cells may be different from that of cells undergoing initial treat-
ments. We found that a high concentration of 5-Fu could upregu-
late 14-3-3r and p53 in a time-dependent manner and
downregulate survivin and bcl-2. Although p-Akt and NF-kB ﬁrst
increased, they ultimately decreased. These results suggest that
initial chemotherapy triggers both cell death and survival pro-
grams, thus demonstrating the complex response to anticancer
treatment. Both molecular mechanisms responsible for resistance
and the initial treatment response should be explored to promote
beneﬁcial chemotherapy effects and reverse resistance. In resistant
cells, there is a regulatory loop between 14-3-3r and p53, but how
5-Fu induces different cellular changes with low or high concentra-
tions requires further study. Our study provides a very useful mod-
el to clarify the resistance mechanism. As a cellular inhibitor of Akt,
14-3-3r would prove useful in the treatment of tumours with ele-
vated Akt activity and Akt-mediated resistance.
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